Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7B9 | ISIN: US92941V3087 | Ticker-Symbol: 26JB
NASDAQ
27.06.25 | 17:21
1,690 US-Dollar
+3,05 % +0,050
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.05.VYNE Therapeutics Inc. - 10-Q, Quarterly Report5
08.05.VYNE Therapeutics Inc. - 8-K, Current Report-
25.04.Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience730OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over...
► Artikel lesen
25.04.VYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 Program176BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) verbally informed...
► Artikel lesen
06.03.VYNE Therapeutics Inc. - 10-K, Annual Report-
06.03.VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)2
VYNE THERAPEUTICS Aktie jetzt für 0€ handeln
06.03.VYNE Therapeutics Inc. - 8-K, Current Report-
19.02.VYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis186Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designed...
► Artikel lesen
17.01.Hedge Fund and Insider Trading News: Scott Bessent, Boaz Weinstein, Warren Buffett, Two Sigma Advisors, Alden Global Capital, Avenue Capital, Vyne Therapeutics Inc (VYNE), Occidental Petroleum Corp (OXY), and More50
13.01.VYNE Therapeutics Inc. - 8-K, Current Report1
06.01.Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics3
06.01.VYNE Therapeutics Inc.: VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo193Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025"Repibresib" approved as the non-proprietary...
► Artikel lesen
23.12.24VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor180Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable...
► Artikel lesen
07.11.24VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update194VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data...
► Artikel lesen
12.09.24VYNE Therapeutics Inc.: VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor210VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement...
► Artikel lesen
14.08.24VYNE Therapeutics Inc.: VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update249Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1